scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1006397256 |
P356 | DOI | 10.1038/SJ.BJC.6604442 |
P932 | PMC publication ID | 2453025 |
P698 | PubMed publication ID | 18542071 |
P5875 | ResearchGate publication ID | 5315485 |
P50 | author | Armando Santoro | Q56335956 |
Alessandra Bearz | Q57079928 | ||
Federico Cappuzzo | Q37392605 | ||
Adolfo Favaretto | Q38641988 | ||
Francesco Grossi | Q52665537 | ||
P2093 | author name string | A Santoro | |
V Torri | |||
M Marangolo | |||
A Ceribelli | |||
B Castagneto | |||
G L Ceresoli | |||
M Mencoboni | |||
D Cortinovis | |||
P A Zucali | |||
F De Vincenzo | |||
G Del Conte | |||
S Salamina | |||
P2860 | cites work | Survival from rare cancer in adults: a population-based study | Q54006928 |
A Survey of Exact Inference for Contingency Tables | Q56432188 | ||
Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer | Q60449339 | ||
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma | Q61628213 | ||
Underrepresentation of patients 65 years of age or older in cancer-treatment trials | Q73311140 | ||
Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration | Q81002008 | ||
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma | Q82892136 | ||
Severe rhabdomyolysis associated with pemetrexed-based chemotherapy | Q83017468 | ||
Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. | Q33196736 | ||
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study | Q33348171 | ||
Pemetrexed in malignant pleural mesothelioma. | Q33364969 | ||
Aging and cancer in America. Demographic and epidemiologic perspectives | Q33841117 | ||
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma | Q34214330 | ||
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group | Q34295028 | ||
Advances in malignant mesothelioma | Q34459139 | ||
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients | Q34485292 | ||
Multidisciplinary treatment of malignant pleural mesothelioma | Q34659099 | ||
Pleural mesothelioma: little evidence, still time to do trials | Q35903121 | ||
Biology and management of malignant pleural mesothelioma. | Q36600505 | ||
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. | Q36617025 | ||
Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups | Q36777126 | ||
Comprehensive geriatric assessment for older patients with cancer | Q36815525 | ||
International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature. | Q36815528 | ||
Assessment of tumor response in malignant pleural mesothelioma | Q36926206 | ||
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group | Q39214897 | ||
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma | Q44102242 | ||
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. | Q44267257 | ||
Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma | Q44405249 | ||
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst | Q46726893 | ||
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). | Q46835349 | ||
Participation of patients 65 years of age or older in cancer clinical trials | Q48006693 | ||
Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models. | Q50754874 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | carboplatin | Q415588 |
malignant pleural mesothelioma | Q18557602 | ||
phase II clinical trial | Q42824440 | ||
P304 | page(s) | 51-56 | |
P577 | publication date | 2008-06-10 | |
P1433 | published in | British Journal of Cancer | Q326309 |
P1476 | title | Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials | |
P478 | volume | 99 |
Q37090808 | Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future |
Q52672893 | Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. |
Q41847770 | FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma |
Q33914000 | Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma |
Q36821171 | Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma |
Q37449036 | Future developments in the management of malignant pleural mesothelioma |
Q55346721 | Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy. |
Q56976088 | Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53 |
Q34293068 | Investigational approaches for mesothelioma |
Q34513958 | Malignant pleural mesothelioma: an update on diagnosis and treatment options |
Q37529848 | Malignant pleural mesothelioma: current treatments and emerging drugs. |
Q43916997 | Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. |
Q37866663 | Medical treatment of mesothelioma: anything new? |
Q58580151 | Multimodality treatment of malignant pleural mesothelioma |
Q33890499 | Novel systemic therapy against malignant pleural mesothelioma |
Q36322856 | Optimization of response classification criteria for patients with malignant pleural mesothelioma. |
Q33918135 | Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey |
Q45020726 | Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. |
Q92591513 | Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy |
Q37290519 | Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy. |
Q37992694 | Systemic treatment of malignant pleural mesothelioma |
Q37260408 | Systemic treatments for mesothelioma: standard and novel |
Q90808642 | Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial |
Q40466065 | miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. |
Q42412951 | microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma. |
Search more.